Risk and Predictability of Drug Interactions in the Elderly

International Review of Neurobiology

Volumn 81, Issue , 2007, Pages 235-251

  Levy, René H ^a,b   Collins, Carol ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARDIOVASCULAR AGENT; NEUROLEPTIC AGENT;

AGED; AGING; DEMENTIA; DRUG INTERACTION; HUMAN; REVIEW; RISK ASSESSMENT;

AGED; AGING; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR AGENTS; DEMENTIA; DRUG INTERACTIONS; HUMANS; RISK ASSESSMENT;

EID: 34047206447     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7742(06)81015-9     Document Type: Review

References (106)

1. Ahmad S. Gemfibrozil interaction with warfarin sodium (coumadin). Chest 98 (1990) 1041-1042
2. Ahmad S. Lovastatin. Warfarin interaction. Arch. Intern. Med. 150 (1990) 2407
3. Albers L.J., Reist C., Vu R.L., Fujimoto K., Ozdemir V., Helmeste D., Poland R., and Tang S.W. Effect of venlafaxine on imipramine metabolism. Psychiatry Res. 96 (2000) 235-243
4. Amchin J., Zarycranski W., Taylor K.P., Albano D., and Klockowski P.M. Effect of venlafaxine on the pharmacokinetics of alprazolam. Psychopharmacol. Bull. 34 (1998) 211-219
5. Amchin J., Ereshefsky L., Zarycranski W., Taylor K., Albano D., and Klockowski P.M. Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe. J. Clin. Pharmacol. 41 (2001) 443-451
6. Andersen B.B., Mikkelsen M., Vesterager A., Dam M., Kristensen H.B., Pedersen B., Lund J., and Mengel H. No influence of the antidepressant paroxetine on carbamazepine, valproate and phenytoin. Epilepsy Res. 10 (1991) 201-204
7. Anderson G.D. Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs. Neurology 63 (2004) S3-S8
8. Anderson G.D., Yau M.K., Gidal B.E., Harris S.J., Levy R.H., Lai A.A., Wolf K.B., Wargin W.A., and Dren A.T. Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin. Pharmacol. Ther. 60 (1996) 145-156
9. Aronoff G.R., Bergstrom R.F., Pottratz S.T., Sloan R.S., Wolen R.L., and Lemberger L. Fluoxetine kinetics and protein binding in normal and impaired renal function. Clin. Pharmacol. Ther. 36 (1984) 138-144
10. Bahls F.H., Ozuna J., and Ritchie D.E. Interactions between calcium channel blockers and the anticonvulsants carbamazepine and phenytoin. Neurology 41 (1991) 740-742
11. Bertilsson L., Dahl M.L., Dalen P., and Al-Shurbaji A. Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs. Br. J. Clin. Pharmacol. 53 (2002) 111-122
12. Bourrie M., Meunier V., Berger Y., and Fabre G. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes. Drug Metab. Dispos. 27 (1999) 288-296
13. Brown R.I., and Cooper T.G. Ticlopidine-carbamazepine interaction in a coronary stent patient. Can. J. Cardiol. 13 (1997) 853-854
14. Caccia S. Metabolism of the newest antidepressants: Comparisons with related predecessors. IDrugs 7 (2004) 143-150
15. Cai W.M., Chen B., Zhou Y., and Zhang Y.D. Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers. Clin. Pharmacol. Ther. 66 (1999) 516-521
16. Clarke W.R., Horn J.R., Kawabori I., and Gurtel S. Potentially serious drug interactions secondary to high-dose diltiazem used in the treatment of pulmonary hypertension. Pharmacotherapy 13 (1993) 402-405
17. Darley J. Interaction between phenytoin and fluoxetine. Seizure 3 (1994) 151-152
18. Dent L.A., and Orrock M.W. Warfarin-fluoxetine and diazepam-fluoxetine interaction. Pharmacotherapy 17 (1997) 170-172
19. DeToledo J.C. Changing presentation of seizures with aging: Clinical and etiological factors. Gerontology 45 (1999) 329-335
20. Donahue S., Flockhart D.A., and Abernethy D.R. Ticlopidine inhibits phenytoin clearance. Clin. Pharmacol. Ther. 66 (1999) 563-568
21. Eimer M., and Carter B.L. Elevated serum carbamazepine concentrations following diltiazem initiation. Drug Intell. Clin. Pharm. 21 (1987) 340-342
22. Eisai Inc. Aricept (donepezil hydrochloride) package insert (2005), Eisai Inc., Teaneck, NJ
23. Eli Lilly and Company. Prozac (fluoxetine hydrochloride) package insert (2005), Eli Lilly and Company, Indianapolis, IN
24. Ellis J.M. Cholinesterase inhibitors in the treatment of dementia. J. Am. Osteopath. Assoc. 105 (2005) 145-158
25. Ereshefsky L., Riesenman C., and Lam Y.W. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. Clin. Pharmacokinet. 29 Suppl. 1 (1995) 10-18 discussion 18-19
26. Fischer T.L., Pieper J.A., Graff D.W., Rodgers J.E., Fischer J.D., Parnell K.J., Goldstein J.A., Greenwood R., and Patterson J.H. Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers. Clin. Pharmacol. Ther. 72 (2002) 238-246
27. Flockhart D.A., and Tanus-Santos J.E. Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch. Intern. Med. 162 (2002) 405-412
28. Forest Pharmaceuticals, Inc. Celexa (citalopram hydrobromide) package insert (2005), Forest Laboratories, Inc., St. Louis, MO
29. Forest Pharmaceuticals, Inc. Lexapro (escitalopram oxalate) package insert (2005), Forest Laboratories, Inc., St. Louis, MO
30. Forest Pharmaceuticals, Inc. Namenda (memantine hydrochloride) package insert (2005), Forest Laboratories, Inc., St. Louis, MO
31. Gidal B.E., Anderson G.D., Seaton T.L., Miyoshi H.R., and Wilenksy A.J. Evaluation of the effect of fluoxetine on the formation of carbamazepine epoxide. Ther. Drug Monit. 15 (1993) 405-409
32. GlaxoSmithKline. Paxil (paroxetine hydrochloride) package insert (2006), GlaxoSmithKline, Research Triangle Park, NC
33. Gorelick P.B., Sacco R.L., Smith D.B., Alberts M., Mustone-Alexander L., Rader D., Ross J.L., Raps E., Ozer M.N., Brass L.M., Malone M.E., Goldberg S., et al. Prevention of a first stroke: A review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. J. Am. Med. Assoc. 281 (1999) 1112-1120
34. Graff D.W., Williamson K.M., Pieper J.A., Carson S.W., Adams Jr. K.F., Cascio W.E., and Patterson J.H. Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. J. Clin. Pharmacol. 41 (2001) 97-106
35. Grasmader K., Verwohlt P.L., Rietschel M., Dragicevic A., Muller M., Hiemke C., Freymann N., Zobel A., Maier W., and Rao M.L. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur. J. Clin. Pharmacol. 60 (2004) 329-336
36. Grimsley S.R., Jann M.W., Carter J.G., D'Mello A.P., and D'Souza M.J. Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin. Pharmacol. Ther. 50 (1991) 10-15
37. Hachad H., Ragueneau-Majlessi I., and Levy R.H. New antiepileptic drugs: Review on drug interactions. Ther. Drug Monit. 24 (2002) 91-103
38. Hansen J.M., Siersboek-Nielsen K., and Skovsted L. Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man. Clin. Pharmacol. Ther. 12 (1971) 539-543
39. Haselberger M.B., Freedman L.S., and Tolbert S. Elevated serum phenytoin concentrations associated with coadministration of sertraline. J. Clin. Psychopharmacol. 17 (1997) 107-109
40. Hauser W.A. Seizure disorders: The changes with age. Epilepsia 33 Suppl. 4 (1992) S6-S14
41. Hemeryck A., Lefebvre R.A., De Vriendt C., and Belpaire F.M. Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin. Pharmacol. Ther. 67 (2000) 283-291
42. Honig L.S., Tang M.X., Albert S., Costa R., Luchsinger J., Manly J., Stern Y., and Mayeux R. Stroke and the risk of Alzheimer disease. Arch. Neurol. 60 (2003) 1707-1712
43. Hoyer J., Schulte K.L., and Lenz T. Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure. Clin. Pharmacokinet. 24 (1993) 230-254
44. Jalil P. Toxic reaction following the combined administration of fluoxetine and phenytoin: Two case reports. J. Neurol. Neurosurg. Psychiatry 55 (1992) 412-413
45. Joblin M. Possible interaction of sertraline with carbamazepine. N. Z. Med. J. 107 (1994) 43
46. Johnson J.A., Herring V.L., Wolfe M.S., and Relling M.V. CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences. J. Pharmacol. Exp. Ther. 294 (2000) 1099-1105
47. Kaminsky L.S., and Zhang Z.Y. Human P450 metabolism of warfarin. Pharmacol. Ther. 73 (1997) 67-74
48. Kanner A.M. Depression in epilepsy: Prevalence, clinical semiology, pathogenic mechanisms, and treatment. Biol. Psychiatry 54 (2003) 388-398
49. Kaufman K.R., and Gerner R. Lamotrigine toxicity secondary to sertraline. Seizure 7 (1998) 163-165
50. Kendall A.G., and Boivin M. Warfarin-carbamazepine interaction. Ann. Intern. Med. 94 (1981) 280
51. Klaassen S.L. Ticlopidine-induced phenytoin toxicity. Ann. Pharmacother. 32 (1998) 1295-1298
52. Kobayashi K., Ishizuka T., Shimada N., Yoshimura Y., Kamijima K., and Chiba K. Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro. Drug Metab. Dispos. 27 (1999) 763-766
53. Kramer G. Epilepsy in the elderly: Some clinical and pharmacotherapeutic aspects. Epilepsia 42 Suppl. 3 (2001) 55-59
54. Kramer G., Tettenborn B., Klosterskov Jensen P., Menge G.P., and Stoll K.D. Oxcarbazepine does not affect the anticoagulant activity of warfarin. Epilepsia 33 (1992) 1145-1148
55. Kudo S., Uchida M., and Odomi M. Metabolism of carteolol by cDNA-expressed human cytochrome P450. Eur. J. Clin. Pharmacol. 52 (1997) 479-485
56. Lackner T.E., Cloyd J.C., Thomas L.W., and Leppik I.E. Antiepileptic drug use in nursing home residents: Effect of age, gender, and comedication on patterns of use. Epilepsia 39 (1998) 1083-1087
57. Lane R.M. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int. Clin. Psychopharmacol. 11 Suppl. 5 (1996) 31-61
58. Larson S.L., Owens P.L., Ford D., and Eaton W. Depressive disorder, dysthymia, and risk of stroke: Thirteen-year follow-up from the Baltimore epidemiologic catchment area study. Stroke 32 (2001) 1979-1983
59. Leinonen E., Lepola U., and Koponen H. Substituting carbamazepine with oxcarbazepine increases citalopram levels. A report on two cases. Pharmacopsychiatry 29 (1996) 156-158
60. Lessard E., Yessine M.A., Hamelin B.A., O'Hara G., LeBlanc J., and Turgeon J. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 9 (1999) 435-443
61. Lossius M.I., Ronning O.M., Mowinckel P., and Gjerstad L. Incidence and predictors for post-stroke epilepsy. A prospective controlled trial. The Akershus stroke study. Eur. J. Neurol. 9 (2002) 365-368
62. Macphee G.J., McInnes G.T., Thompson G.G., and Brodie M.J. Verapamil potentiates carbamazepine neurotoxicity: A clinically important inhibitory interaction. Lancet 1 8483 (1986) 700-703
63. Mantyla R., Mannisto P., Nykanen S., Koponen A., and Lamminsivu U. Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. Eur. J. Clin. Pharmacol. 24 (1983) 227-230
64. Margolis J.M., O'Donnell J.P., Mankowski D.C., Ekins S., and Obach R.S. (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab. Dispos. 28 (2000) 1187-1191
65. Massey E.W. Effect of carbamazepine on Coumadin metabolism. Ann. Neurol. 13 (1983) 691-692
66. Michelucci R., Cipolla G., Passarelli D., Gatti G., Ochan M., Heinig R., Tassinari C.A., and Perucca E. Reduced plasma nisoldipine concentrations in phenytoin-treated patients with epilepsy. Epilepsia 37 (1996) 1107-1110
67. Moller S.E., Larsen F., Khant A.Z., and Rolan P.E. Lack of effect of citalopram on the steady-state pharmacokinetics of carbamazepine in healthy male subjects. J. Clin. Psychopharmacol. 21 (2001) 493-499
68. Murphy M.J., and Dominiczak M.H. Efficacy of statin therapy: Possible effect of phenytoin. Postgrad. Med. J. 75 (1999) 359-360
69. Nappi J.M. Warfarin and phenytoin interaction. Ann. Intern. Med. 90 (1979) 852
70. Novartis Pharmaceuticals Corp. Exelon (rivastigmine tartrate) package insert (2006), Novartis Pharmaceuticals Corp., East Hanover, NJ
71. Novartis Pharmaceuticals Corp. Trileptal (oxcarbazepine) package insert (2006), Novartis Pharmaceuticals Corp., East Hanover, NJ
72. Ogilvie B.W., Zhang D., Li W., Rodrigues A.D., Gipson A.E., Holsapple J., Toren P., and Parkinson A. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: Implications for drug-drug interactions. Drug Metab. Dispos. 34 (2006) 191-197
73. Oldham H.G., and Clarke S.E. In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. Drug Metab. Dispos. 25 (1997) 970-977
74. Organon, USA Inc. Remeron (mirtazapine) package insert (2005), Organon USA Inc., West Orange, NJ
75. Ortho-McNeil Neurologies Inc. Razadyne ER (galantamine HBr) package insert (2005), Ortho-McNeil Neurologies, Inc., Titusville, NJ
76. Perucca E., Berlowitz D., Birnbaum A., Cloyd J.C., Garrard J., Hanlon J.T., Levy R.H., and Pugh M.J. Pharmacological and clinical aspects of antiepileptic drug use in the elderly. Epilepsy Res. 68 Suppl. 1 (2006) S49-S63
77. Pfizer Inc. Zoloft (sertraline hydrochloride) package insert (2006), Pfizer Inc., New York, NY
78. Pihlsgard M., and Eliasson E. Significant reduction of sertraline plasma levels by carbamazepine and phenytoin. Eur. J. Clin. Pharmacol. 57 (2002) 915-916
79. Prueksaritanont T., Zhao J.J., Ma B., Roadcap B.A., Tang C., Qiu Y., Liu L., Lin J.H., Pearson P.G., and Baillie T.A. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J. Pharmacol. Exp. Ther. 301 (2002) 1042-1051
80. Ragueneau-Majlessi I., Levy R.H., and Meyerhoff C. Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin. Epilepsy Res. 47 (2001) 55-63
81. Rapeport W.G., Muirhead D.C., Williams S.A., Cross M., and Wesnes K. Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. J. Clin. Psychiatry 57 Suppl. 1 (1996) 24-28
82. Rapeport W.G., Williams S.A., Muirhead D.C., Dewland P.M., Tanner T., and Wesnes K. Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. J. Clin. Psychiatry 57 Suppl. 1 (1996) 20-23
83. Ringman J.M., and Cummings J.L. Current and emerging pharmacological treatment options for dementia. Behav. Neurol. 17 (2006) 5-16
84. Riva R., Cerullo A., Albani F., and Baruzzi A. Ticlopidine impairs phenytoin clearance: A case report. Neurology 46 (1996) 1172-1173
85. Robinson R.G. Poststroke depression: Prevalence, diagnosis, treatment, and disease progression. Biol. Psychiatry 54 (2003) 376-387
86. Rutledge D.R., Pieper J.A., and Mirvis D.M. Effects of chronic phenobarbital on verapamil disposition in humans. J. Pharmacol. Exp. Ther. 246 (1988) 7-13
87. Shitara Y., and Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol. Ther. (2006) May 19, 2006 [Epub ahead of print]
88. Shitara Y., Hirano M., Sato H., and Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: Analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther. 311 (2004) 228-236
89. Sidhu J., Job S., Singh S., and Philipson R. The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br. J. Clin. Pharmacol. 61 (2006) 191-199
90. Sitsen J., Maris F., and Timmer C. Drug-drug interaction studies with mirtazapine and carbamazepine in healthy male subjects. Eur. J. Drug Metab. Pharmacokinet. 26 (2001) 109-121
91. Skinner M.H., Kuan H.Y., Pan A., Sathirakul K., Knadler M.P., Gonzales C.R., Yeo K.P., Reddy S., Lim M., Ayan-Oshodi M., and Wise S.D. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin. Pharmacol. Ther. 73 (2003) 170-177
92. Spaans E., van den Heuvel M.W., Schnabel P.G., Peeters P.A., Chin-Kon-Sung U.G., Colbers E.P., and Sitsen J.M. Concomitant use of mirtazapine and phenytoin: A drug-drug interaction study in healthy male subjects. Eur. J. Clin. Pharmacol. 58 (2002) 423-429
93. Stearns R.A., Chakravarty P.K., Chen R., and Chiu S.H. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug Metab. Dispos. 23 (1995) 207-215
94. Steinacher L., Vandel P., Zullino D.F., Eap C.B., Brawand-Amey M., and Baumann P. Carbamazepine augmentation in depressive patients non-responding to citalopram: A pharmacokinetic and clinical pilot study. Eur. Neuropsychopharmacol. 12 (2002) 255-260
95. Stephen L.J., and Brodie M.J. Epilepsy in elderly people. Lancet 355 (2000) 1441-1446
96. Stormer E., von Moltke L.L., Shader R.I., and Greenblatt D.J. Metabolism of the antidepressant mirtazapine in vitro: Contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab. Dispos. 28 (2000) 1168-1175
97. Tartara A., Galimberti C.A., Manni R., Parietti L., Zucca C., Baasch H., Caresia L., Muck W., Barzaghi N., Gatti G., and Perucca E. Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. Br. J. Clin. Pharmacol. 32 (1991) 335-340
98. Trilli L.E., Kelley C.L., Aspinall S.L., and Kroner B.A. Potential interaction between warfarin and fluvastatin. Ann. Pharmacother. 30 (1996) 1399-1402
99. Turnheim K. When drug therapy gets old: Pharmacokinetics and pharmacodynamics in the elderly. Exp. Gerontol. 38 (2003) 843-853
100. von Moltke L.L., Duan S.X., Greenblatt D.J., Fogelman S.M., Schmider J., Harmatz J.S., and Shader R.I. Venlafaxine and metabolites are very weak inhibitors of human cytochrome P450-3A isoforms. Biol. Psychiatry 41 (1997) 377-380
101. von Moltke L.L., Greenblatt D.J., Grassi J.M., Granda B.W., Venkatakrishnan K., Duan S.X., Fogelman S.M., Harmatz J.S., and Shader R.I. Citalopram and desmethylcitalopram in vitro: Human cytochromes mediating transformation, and cytochrome inhibitory effects. Biol. Psychiatry 46 (1999) 839-849
102. von Moltke L.L., Greenblatt D.J., Giancarlo G.M., Granda B.W., Harmatz J.S., and Shader R.I. Escitalopram (S-citalopram) and its metabolites in vitro: Cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab. Dispos. 29 (2001) 1102-1109
103. Wen X., Wang J.S., Backman J.T., Kivisto K.T., and Neuvonen P.J. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab. Dispos. 29 (2001) 1359-1361
104. Wienkers L.C., Wurden C.J., Storch E., Kunze K.L., Rettie A.E., and Trager W.F. Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metab. Dispos. 24 (1996) 610-614
105. Yasui-Furukori N., and Tateishi T. Carbamazepine decreases antihypertensive effect of nilvadipine. J. Clin. Pharmacol. 42 (2002) 100-103
106. Zaccara G., Gangemi P.F., Bendoni L., Menge G.P., Schwabe S., and Monza G.C. Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine. Ther. Drug Monit. 15 (1993) 39-42